Comparison of anti-proteinuric effects of febuxostat and conventional therapies for hyperuricemia in patients with chronic kidney disease: an open-label randomized controlled trial
- Conditions
- Hyperuricemia, chronic kidney disease
- Registration Number
- JPRN-UMIN000009942
- Lead Sponsor
- Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Not provided
1) High-risk patients requiring dialysis or renal transplantation within 48 weeks 2) History of gout 3) Patients with Cancer or liver disease (HBV/HCV hepatitis, cirrhosis, and the other liver injuries showing AST/ALT values more than twice as high of normal values 4) HbA1c (JDS) >-7.0% with 2 months prior to the entry 5) Office systolic blood pressure >-160 mmHg or diastolic blood pressure >-100 mmHg both at recent twice office visits before the entry 6) Severe heart failure or edema 7) History of renal replacement therapy 8) History of febuxostat intake within four weeks before the entry 9) History of hypersensitivity to allopurinol, benzbromarone, or febuxostat 10) Judged as ineligible in the opinion of the attending physician 11) Pregnancy or nursing
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rinary protein creatinine ratio at 24 weeks after treatments
- Secondary Outcome Measures
Name Time Method Chronological changes of urinary protein excretion from the baseline to 24 weeks and those from 24 to 48 weeks. Estimated GFR, plasma renin activity, plasma aldosterone concentration, urinary albumin creatinine ratio, urinary L-FABP, urinary 8-OHdG, serum methylglyoxal, and blood pressure